Evidence map›Paper›PMID 24759636›Full record

ArticleNeuro-oncology2014

MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.

Shahrzad Jalali, Caroline Chung, Warren Foltz, Kelly Burrell, Sanjay Singh, Richard Hill, Gelareh Zadeh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. [Laboratory animal research · 2018
    Article
  10. Article
  11. Recruitment of CD11bOncology letters · 2017
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shahrzad JalaliBrain Tumor Research Center, Hospital for Sick Children, Toronto, Canada (S.J., K.B., S.S., G.Z.); Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada (C.C., W.F.); Department of Radiation Oncology, University of Toronto, Toronto, Canada (W.F., R.H.); Ontario Cancer Institute, Princess Margaret Cancer Centre, and Department of Medical Biophysics, University of Toronto, Toronto, Canada (R.H.); Division of Neurosurgery, University of Toronto and Toronto Western Hospital, University Health Network, Toronto, Canada (G.Z.).
Caroline ChungBrain Tumor Research Center, Hospital for Sick Children, Toronto, Canada (S.J., K.B., S.S., G.Z.); Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada (C.C., W.F.); Department of Radiation Oncology, University of Toronto, Toronto, Canada (W.F., R.H.); Ontario Cancer Institute, Princess Margaret Cancer Centre, and Department of Medical Biophysics, University of Toronto, Toronto, Canada (R.H.); Division of Neurosurgery, University of Toronto and Toronto Western Hospital, University Health Network, Toronto, Canada (G.Z.).
Warren FoltzBrain Tumor Research Center, Hospital for Sick Children, Toronto, Canada (S.J., K.B., S.S., G.Z.); Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada (C.C., W.F.); Department of Radiation Oncology, University of Toronto, Toronto, Canada (W.F., R.H.); Ontario Cancer Institute, Princess Margaret Cancer Centre, and Department of Medical Biophysics, University of Toronto, Toronto, Canada (R.H.); Division of Neurosurgery, University of Toronto and Toronto Western Hospital, University Health Network, Toronto, Canada (G.Z.).
Kelly BurrellBrain Tumor Research Center, Hospital for Sick Children, Toronto, Canada (S.J., K.B., S.S., G.Z.); Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada (C.C., W.F.); Department of Radiation Oncology, University of Toronto, Toronto, Canada (W.F., R.H.); Ontario Cancer Institute, Princess Margaret Cancer Centre, and Department of Medical Biophysics, University of Toronto, Toronto, Canada (R.H.); Division of Neurosurgery, University of Toronto and Toronto Western Hospital, University Health Network, Toronto, Canada (G.Z.).
Sanjay SinghBrain Tumor Research Center, Hospital for Sick Children, Toronto, Canada (S.J., K.B., S.S., G.Z.); Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada (C.C., W.F.); Department of Radiation Oncology, University of Toronto, Toronto, Canada (W.F., R.H.); Ontario Cancer Institute, Princess Margaret Cancer Centre, and Department of Medical Biophysics, University of Toronto, Toronto, Canada (R.H.); Division of Neurosurgery, University of Toronto and Toronto Western Hospital, University Health Network, Toronto, Canada (G.Z.).
Richard HillBrain Tumor Research Center, Hospital for Sick Children, Toronto, Canada (S.J., K.B., S.S., G.Z.); Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada (C.C., W.F.); Department of Radiation Oncology, University of Toronto, Toronto, Canada (W.F., R.H.); Ontario Cancer Institute, Princess Margaret Cancer Centre, and Department of Medical Biophysics, University of Toronto, Toronto, Canada (R.H.); Division of Neurosurgery, University of Toronto and Toronto Western Hospital, University Health Network, Toronto, Canada (G.Z.).
Gelareh ZadehBrain Tumor Research Center, Hospital for Sick Children, Toronto, Canada (S.J., K.B., S.S., G.Z.); Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada (C.C., W.F.); Department of Radiation Oncology, University of Toronto, Toronto, Canada (W.F., R.H.); Ontario Cancer Institute, Princess Margaret Cancer Centre, and Department of Medical Biophysics, University of Toronto, Toronto, Canada (R.H.); Division of Neurosurgery, University of Toronto and Toronto Western Hospital, University Health Network, Toronto, Canada (G.Z.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough anti-angiogenic therapy (AATx) holds great promise for treatment of malignant gliomas, its therapeutic efficacy is not well understood and can potentially increase the aggressive recurrence of gliomas. It is essential to establish sensitive, noninvasive biomarkers that can detect failure of AATx and tumor recurrence early so that timely adaptive therapy can be instituted. We investigated the efficacy of MRI biomarkers that can detect response to different classes of AATxs used alone or in combination with radiation.

methodsMurine intracranial glioma xenografts (NOD/SCID) were treated with sunitinib, VEGF-trap or B20 (a bevacizumab equivalent) alone or in combination with radiation. MRI images were acquired longitudinally before and after treatment, and various MRI parameters (apparent diffusion coefficient, T1w + contrast, dynamic contrast-enhanced [DCE], initial area under the contrast enhancement curve, and cerebral blood flow) were correlated to tumor cell proliferation, overall tumor growth, and tumor vascularity.

resultsCombinatorial therapies reduced tumor growth rate more efficiently than monotherapies. Apparent diffusion coefficient was an accurate measure of tumor cell density. Vascular endothelial growth factor (VEGF)-trap or B20, but not sunitinib, resulted in significant reduction or complete loss of contrast enhancement. This reduction was not due to a reduction in tumor growth or microvascular density, but rather was explained by a reduction in vessel permeability and perfusion. We established that contrast enhancement does not accurately reflect tumor volume or vascular density; however, DCE-derived parameters can be used as efficient noninvasive biomarkers of response to AATx.

conclusionsMRI parameters following therapy vary based on class of AATx. Validation of clinically relevant MRI parameters for individual AATx agents is necessary before incorporation into routine practice.

Indexed as

Magnetic Resonance ImagingAngiogenesis InhibitorsAnimalsAntibodies, Monoclonal, HumanizedBevacizumabBiomarkersBrain NeoplasmsCell Line, TumorCombined Modality TherapyGlioblastomaHumansImage Processing, Computer-AssistedIndolesMicePyrrolesReceptors, Vascular Endothelial Growth FactorafliberceptAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBiomarkersIndolesPyrrolesReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsSunitinibanti-angiogenic therapiesglioblastoma multiforme (GBM)MRI biomarker

Identifiers

PMID24759636
PMCPMC4022230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.